Merck

MK-3475-756

NCT03725059

JGB-1806

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Status:

Recruiting

26459-200.png

III

Phase

Line of Therapy.png

Neoadjuvant

Line of Therapy

Disease Stage.png

Early Cancer

Disease Stage

Target.png

Biomarker(s)

HER2-, ER+

Investigational

Product

Pembrolizumab+Chemotherapy (KX/KA[E]C)

Treatment Arms

oPembrolizumab+Chemotherapy (KX/KA[E]C)
oPlacebo+Chemotherapy (PX/PA[E]C)